Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Pacira initiated with a Buy at SunTrust » 16:20
01/23/20
01/23
16:20
01/23/20
16:20
PCRX

Pacira

$43.93 /

-0.55 (-1.24%)

SunTrust analyst Greg…

SunTrust analyst Greg Fraser initiated coverage of Pacira BioSciences with a Buy rating and $60 price target. Exparel has been growing well, says the analyst, who expects continued solid growth driven by broadening use for current indications, approval for new indications, and macro tailwinds. He believes Street estimates may be overly conservative and sees more upside potential than downside risk.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Tuesday
Hot Stocks
Pacira, Envision Physician Services collaborate for anesthesia training » 07:41
01/21/20
01/21
07:41
01/21/20
07:41
PCRX

Pacira

$43.77 /

-0.2 (-0.45%)

Pacira BioSciences…

Pacira BioSciences announced a collaboration with Envision Physician Services to train anesthesiology clinicians on ultrasound-guided regional anesthesia techniques utilizing long-acting local anesthetics like EXPAREL via a series of interactive workshops held across the country. The program supports ongoing efforts by both organizations to advance the delivery of high-quality, patient-centered care. Clinicians participating in the comprehensive training sessions will enhance their skills in performing ultrasound-guided interscalene brachial plexus blocks, as well as fascial plane blocks, including transversus abdominis plane, rectus sheath, quadratus lumborum, and pectoralis blocks. Ultrasound-guided infiltration techniques for surgery will also be taught. The curriculum will include the safe use of EXPAREL in regional anesthetic techniques, including administration, admixing, volume expansion, and incorporation into perioperative pain management protocols.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Conference/Events
JPMorgan to hold a conference » 09:58
01/15/20
01/15
09:58
01/15/20
09:58
ABBV

AbbVie

$88.50 /

+0.265 (+0.30%)

, AKRO

Akero Therapeutics

$19.90 /

+0.07 (+0.35%)

, GKOS

Glaukos

$59.98 /

+0.6 (+1.01%)

, MORF

Morphic Holding

$18.99 /

+ (+0.00%)

, RCM

R1 RCM

$13.54 /

+0.01 (+0.07%)

, TWST

Twist Bioscience

$21.82 /

+0.32 (+1.49%)

, XRAY

Dentsply Sirona

$59.02 /

+0.27 (+0.46%)

, QDEL

Quidel

$81.18 /

+0.88 (+1.10%)

, CYCN

Cyclerion Therapeutics

$3.58 /

-0.095 (-2.59%)

, HQY

HealthEquity

$72.39 /

+0.29 (+0.40%)

, PCRX

Pacira

$43.51 /

+0.27 (+0.62%)

, AKBA

Akebia

$6.96 /

+0.06 (+0.87%)

, ALKS

Alkermes

$19.50 /

+0.06 (+0.31%)

, ITCI

Intra-Cellular

$26.97 /

+0.17 (+0.63%)

, AVNS

Avanos

$33.32 /

+0.33 (+1.00%)

, BCRX

BioCryst

$2.81 /

+0.04 (+1.44%)

, NVST

Envista

$31.84 /

+0.345 (+1.10%)

, ANAB

AnaptysBio

$15.31 /

+0.3 (+2.00%)

, TECH

Bio-Techne

$218.01 /

+ (+0.00%)

, TMDX

TransMedics

$19.44 /

+ (+0.00%)

, OBSV

ObsEva

$3.68 /

-0.03 (-0.81%)

, IART

Integra LifeSciences

$58.27 /

-0.23 (-0.39%)

, CRNX

Crinetics

$25.26 /

+ (+0.00%)

38th Annual Healthcare…

38th Annual Healthcare Conference will be held in San Francisco on January 13-16 with webcasted company presentations to begin on January 15 at 10:30 am; not all company presentations may be webcasted. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Pacira management to meet with RBC Capital » 04:55
01/13/20
01/13
04:55
01/13/20
04:55
PCRX

Pacira

$42.42 /

-0.49 (-1.14%)

Meeting to be held in New…

Meeting to be held in New York on January 13 hosted by RBC Capital.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Pacira reports FY19 preliminary revenue $421M, consensus $418.06M » 07:36
01/09/20
01/09
07:36
01/09/20
07:36
PCRX

Pacira

$43.09 /

+0.51 (+1.20%)

Full-year EXPAREL net…

Full-year EXPAREL net product sales were $407.9 million in 2019, compared to $331.1 million in 2018. Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice were $3.2 million in 2019, compared to $1.3 million in 2018. The company's 2019 financial guidance was as follows: EXPAREL net product sales in the range of $400 million to $410 million and iovera degrees net product sales in the range of $8 million to $10 million.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Pacira reports Q4 preliminary revenue $122.4M, consensus $119.7M. » 07:35
01/09/20
01/09
07:35
01/09/20
07:35
PCRX

Pacira

$43.09 /

+0.51 (+1.20%)

"2019 was a year of…

"2019 was a year of outstanding results led by strong EXPAREL revenue growth as it becomes a critical mainstay of anesthesiologists' opioid-sparing strategies for a wide range of soft tissue and orthopedic procedures. In addition, we successfully advanced the initial commercial rollout of iovera degrees , which we believe positions us to become the preferred provider of opioid-sparing pain management for both inpatient and ambulatory surgeries," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "As we look ahead to 2020 and beyond, we expect continued topline growth to drive substantial operating leverage and cash flow, providing us with significant financial flexibility to capitalize on internal and external growth opportunities that support our global leadership position in innovative, non-opioid pain management." Fourth quarter net product sales of EXPAREL/bupivacaine liposome injectable suspension were $118.6 million in 2019, compared to $94.7 million in 2018. Fourth quarter EXPAREL net product sales were $116.9 million in 2019, compared to $94.4 million in 2018. Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice were $1.7 million in 2019, compared to $0.3 million in 2018. Fourth quarter iovera degrees net product sales were $3.2 million in 2019. Full-year iovera degrees net product sales were $7.9 million in 2019. Pacira began recognizing sales of iovera degrees in April 2019 after completing its acquisition of MyoScience, Inc., a privately held medical technology company. Fourth quarter royalty revenue was $0.6 million and full-year was $2.1 million; compared to $0.4 million and $1.9 million in 2018, respectively.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Pacira management to meet with RBC Capital » 07:21
01/08/20
01/08
07:21
01/08/20
07:21
PCRX

Pacira

$42.58 /

-1.3 (-2.96%)

Meeting to be held in New…

Meeting to be held in New York on January 13 hosted by RBC Capital.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Sarepta, Pacira, Protagonist named top 2020 Biotech picks at BTIG » 07:50
01/07/20
01/07
07:50
01/07/20
07:50
SRPT

Sarepta

$131.45 /

+1.78 (+1.37%)

, PCRX

Pacira

$43.88 /

-0.8 (-1.79%)

, PTGX

Protagonist Therapeutics

$6.68 /

+0.08 (+1.21%)

Sarepta Therapeutics…

Sarepta Therapeutics (SRPT), Pacira Biosciences (PCRX) and Protagonist Therapeutics (PGTX) are BTIG's top Biotech picks for 2020, analyst Timothy Chiang tells investors in a research note. He believes Sarepta shares have the potential for "significant outperformance" in the next 12 months based on expected initiation of its commercial supply study with SRP-9001 for the treatment of patients with Duchenne Muscular Dystrophy by mid-2020 and increased visibility on its other gene therapy programs. Pacira shares could be an outperformer in 2020 based on Exparel's "strong momentum," Chiang writes. Meanwhile, shares of Protagonist are "poised to recover" in 2020 with multiple potential data readouts expected. The company has multiple shots on goal with its key pipeline candidates entering Phase 2 studies, including PN-943 in inflammatory bowel disease and PTG-300 for the treatment of beta-thalassemia, polycythemia vera, hereditary hemochromatosis and myelodystplastic syndrome, contends Chiang. He keeps Buy ratings on all three names.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Pacira says EXPAREL achieves primary, secondary endpoints in Phase 4 study » 07:32
01/07/20
01/07
07:32
01/07/20
07:32
PCRX

Pacira

$43.88 /

-0.8 (-1.79%)

Pacira BioSciences…

Pacira BioSciences announced that its Phase 4 study of EXPAREL in patients undergoing Cesarean section achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption while maintaining pain scores through 72 hours. EXPAREL demonstrated statistical significance for the key secondary endpoint of a reduction in the incidence and severity of itching for 72 hours after surgery. Full study results will be submitted for publication in the peer-reviewed medical literature later this year. The Phase 4, multicenter, randomized, active-controlled study across 18 clinical sites in the United States, enrolled 169 patients undergoing elective C-section. Patients were randomized to receive either 150 mcg morphine spinal anesthesia plus standard of care postoperative pain regimen, 50 mcg morphine spinal anesthesia plus EXPAREL transversus abdominis plane field block or opioid-free spinal anesthesia plus EXPAREL TAP block. Patients in the EXPAREL arms received a protocol-defined postoperative pain management regimen comprised of ketorolac, acetaminophen and ibuprofen. All patients could receive opioid rescue pain medicine upon request for breakthrough pain. The company's previous Phase 4 clinical study of EXPAREL in the C-section setting is awaiting publication in a peer-reviewed medical journal. That study demonstrated the superiority of an EXPAREL TAP block to a bupivacaine TAP block in patients undergoing C-section, achieving a 52% reduction in opioid use for EXPAREL-treated patients while also reducing pain scores through 72 hours post-surgery. Importantly, the study demonstrated a statistically significant higher percentage of opioid-spared patients in the EXPAREL group, with EXPAREL treated patients taking no more than one opioid tablet and experiencing no opioid-related side effects through 72 hours.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Conference/Events
Pacira management to meet with BTIG » 04:55
12/19/19
12/19
04:55
12/19/19
04:55
PCRX

Pacira

$46.53 /

+0.69 (+1.51%)

Group Luncheon Meeting to…

Group Luncheon Meeting to be held in New York on December 19 hosted by BTIG.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.
友情链接:幸运飞艇官方开奖2020幸运飞艇计划网幸运飞艇走势图幸运飞艇历史开奖结果筛选